FDA programs
Investigational Device Exemption (IDE): how medical device clinical trials work
Investigational device exemption (IDE) explained: when a device study needs FDA approval, significant vs non-significant risk, and pivotal trials.
By the All In MedTech editorial team · Published November 19, 2026 · 7 min read
An investigational device exemption (IDE) is FDA's permission to use a device that has not been cleared or approved in a clinical study, so the sponsor can collect the safety and effectiveness data needed for a marketing submission. The rules are in 21 CFR Part 812. Whether a study needs FDA's own approval, or only approval from an institutional review board (IRB), depends mainly on whether the device is a significant risk device.
This post walks through what an IDE covers, the significant risk test, the 30-day review, the duties of sponsors and investigators, and how to find device trials.
What an IDE does
Without an exemption, shipping an uncleared, unapproved device for use on people would break several requirements of the Federal Food, Drug, and Cosmetic Act. Section 812.1 says an approved IDE lets the device be shipped lawfully for investigation and exempts it from requirements such as premarket notification and approval, registration and listing, and most of the quality system rules. Design controls under the quality system regulation still apply.
FDA's IDE overview page notes that clinical studies are most often run to support a PMA, while only a small share of 510(k)s need clinical data. An IDE can also cover studies of a new intended use or certain modifications of a device that is already on the market.
An IDE study must still meet the general human subject protection rules:
- informed consent from every subject, under 21 CFR Part 50;
- review and approval by an IRB, under 21 CFR Part 56;
- financial disclosure by clinical investigators, under 21 CFR Part 54;
- labeling of the device as investigational, monitoring of the study, and the records and reports Part 812 requires.
Three kinds of device study
Part 812 sorts device studies into three groups. The group decides what approvals are needed.
| Study type | Who must approve | Basis |
|---|---|---|
| Significant risk (SR) | FDA approves an IDE application, and an IRB approves the study | 21 CFR 812.20, 812.30, 812.42 |
| Non-significant risk (NSR) | IRB only; the study is "considered to have an approved IDE" if abbreviated requirements are met | 21 CFR 812.2(b) |
| Exempt | Part 812 does not apply, apart from the rule on disqualifying investigators | 21 CFR 812.2(c) |
Significant risk devices
Section 812.3(m) defines a significant risk device as an investigational device that presents a potential for serious risk to the health, safety or welfare of a subject and falls into one of these groups:
- it is intended as an implant;
- it is used to support or sustain human life;
- it is for a use of substantial importance in diagnosing, curing, mitigating or treating disease, or preventing impairment of health; or
- it otherwise presents a potential for serious risk to subjects.
The judgment is about the device as it will be used in the study, including the procedure needed to use it. The sponsor makes the first call, but the IRB reviewing an NSR study can disagree. Under section 812.66, if the IRB decides the device is significant risk, it notifies the investigator and, where appropriate, the sponsor, and the study cannot start until the FDA process is followed. FDA can also be asked to make the determination.
Non-significant risk devices
A study of a device that is not significant risk, and not banned, follows the abbreviated requirements in section 812.2(b). The sponsor labels the device correctly, gets and keeps IRB approval after giving the IRB a brief explanation of why the device is not significant risk, ensures informed consent, monitors the study, keeps certain records and makes certain reports, and observes the ban on promotion. No application goes to FDA.
Exempt studies
Section 812.2(c) lists studies Part 812 does not cover. Examples include a legally marketed device used according to its cleared or approved labeling, certain noninvasive diagnostic devices that meet specific conditions, consumer preference testing that does not test safety or effectiveness and puts subjects at no risk, devices for veterinary use only, and custom devices unless they are being studied for commercial distribution.
Applying for an IDE
For a significant risk study, the sponsor submits an IDE application under section 812.20. It includes a complete report of prior investigations, such as bench and animal testing, the investigational plan or a summary of it, a description of how the device is manufactured and controlled, the investigator agreements and list of investigators, the IRBs involved, all labeling, the informed consent materials, and, if the device will be sold, the price and why that sale is not commercialization.
Many sponsors first discuss the study design with FDA through a Pre-Submission, part of the Q-Submission program. This is optional but common for pivotal trials.
The 30-day clock
Section 812.30(a) sets the timing. FDA notifies the sponsor of the date it received the application. The investigation may begin either 30 days after FDA receives the application, unless FDA tells the sponsor the study may not begin, or once FDA approves the IDE by order. The same section says FDA may approve the investigation as proposed, approve it with modifications, or disapprove it, and a disapproval explains what must change. IRB approval is also required before any subject is enrolled.
After approval, changes to the plan generally go to FDA as IDE supplements under section 812.35.
Rules that apply during the study
Section 812.7 bars sponsors and investigators from:
- promoting or test marketing the device before FDA approves it for commercial distribution;
- charging subjects or investigators more than needed to recover manufacturing, research, development and handling costs;
- unduly prolonging a study once the data show the device cannot succeed;
- representing that the device is safe or effective for the use being studied.
Reporting duties are in section 812.150. Two are especially time-sensitive:
- Unanticipated adverse device effects. An investigator must report one to the sponsor and the IRB as soon as possible and no later than 10 working days after learning of it. A sponsor that evaluates such an effect must report the results to FDA, all reviewing IRBs and participating investigators within 10 working days after first receiving notice of it.
- Progress reports. Sponsors report to IRBs at regular intervals and at least yearly. For significant risk devices, progress reports also go to FDA.
Feasibility, pivotal and early feasibility studies
Device development usually runs through stages, each of which may need its own IDE or IDE supplement:
- Early feasibility studies enroll a small number of subjects to test a device concept, often before the design is final. FDA runs an Early Feasibility Studies Program to support doing this work in the United States.
- Traditional feasibility studies test a near-final device to gather preliminary safety and performance data and to plan the pivotal study.
- Pivotal studies are the main source of evidence for the marketing submission. For a PMA they are often larger, controlled, multicenter studies with prespecified endpoints.
A Breakthrough-designated device can ask for prioritized review of its IDE. See the Breakthrough Devices Program for what designation provides.
Medicare and IDE studies
Medicare can pay for some costs in FDA-approved IDE studies. FDA places each IDE device in Category A (experimental) or Category B (nonexperimental or investigational). According to CMS's page on Medicare coverage related to IDE studies, Medicare may cover routine care items and services in Category A studies but not the Category A device itself, while in Category B studies it may cover both the device and routine care. The study has to meet the criteria in 42 CFR Part 405 Subpart B and be approved by CMS. For the wider payment picture, see how medical device reimbursement works.
Finding device trials
Most controlled device trials of FDA-regulated devices, other than small feasibility studies, must be registered on ClinicalTrials.gov under the FDA Amendments Act requirements in 42 CFR Part 11. The registry shows the design, enrollment, status, sites and, often, results. It does not show the IDE number or FDA's significant risk decision, so a registered trial is not proof of an FDA-approved IDE.
Once a device is on the market, the trial record and the FDA decision summary together tell you what evidence supported it. For PMAs, the approval documents describe the pivotal study in detail. See what is PMA for where to find them.
Summary
An IDE lets an unapproved device be used in a clinical study. Significant risk studies need an FDA-approved IDE and IRB approval, and can begin 30 days after FDA receives the application unless FDA objects. Non-significant risk studies need IRB approval and must follow abbreviated requirements. Some studies are exempt. In every case, informed consent, IRB oversight, the ban on promotion and the reporting rules for unanticipated adverse device effects apply.
Frequently asked questions
- What is an investigational device exemption?
- An IDE allows a device that is not yet cleared or approved to be used in a clinical study to collect safety and effectiveness data, under the rules in 21 CFR Part 812.
- Does every device study need FDA approval?
- No. Significant risk studies need an FDA-approved IDE, non-significant risk studies need only IRB approval under abbreviated requirements, and some studies are exempt from Part 812 altogether.
- How long does FDA take to review an IDE?
- Under 21 CFR 812.30, an investigation may begin 30 days after FDA receives the application unless FDA notifies the sponsor that it may not, or earlier if FDA approves it by order.
- What is a pivotal device trial?
- A pivotal study is the main study intended to provide the safety and effectiveness evidence for a marketing submission, usually a PMA, and it typically follows smaller feasibility studies.
For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.